Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Optibiotix Health Plc LSE:OPTI London Ordinary Share GB00BP0RTP38 ORD 2P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -3.00p -3.87% 74.50p 74.00p 75.00p 77.50p 74.50p 77.50p 126,326 15:42:58
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 0.5 -1.9 -2.3 - 63.65

OptiBiotix Health PLC GoFigure® distribution agreement for Poland

22/05/2019 7:00am

UK Regulatory (RNS & others)


Optibiotix Health (LSE:OPTI)
Historical Stock Chart

1 Month : From May 2019 to Jun 2019

Click Here for more Optibiotix Health Charts.

TIDMOPTI

RNS Number : 7617Z

OptiBiotix Health PLC

22 May 2019

OptiBiotix Health plc

("OptiBiotix")

GoFigure(R) distribution agreement for Poland

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high

cholesterol and diabetes, announces it has appointed Extensor as its exclusive distributor of OptiBiotix's own label GoFigure(R) consumer weight management products in Poland.

The agreement grants Extensor the exclusive rights to import, market and distribute OptiBiotix's GoFigure(R) range of meal replacements, flapjacks and mueslis containing its award winning SlimBiome(R) technology within the Polish market. This agreement has been signed accompanied by an initial modest five figure order and registration of gofigure.pl for online promotion of the products within the Polish market.

Extensor is a well-known Polish brand that was established over 19 years ago for the creation and promotion of products with the highest quality and safety levels in the Health and Wellness sector. The company works with world leaders in the whey protein industry and in 2002, introduced high-protein supplements to the Polish market. Extensor has an extensive distribution network across Poland and is sold through multiple on-line channels, wholesalers, and retail outlets across shops in Poland.

This agreement is a strategic step to take OptiBiotix's own label GoFigure(R) products to international markets. This builds GoFigure(R) brand recognition, enhancing brand value, and creates a further demand for SlimBiome(R), the functional ingredient within Gofigure(R) products.

Christina Wood, Sales & Marketing Director commented: "We are pleased to announce this exclusive distribution deal for the commercialisation of our GoFigure(R) products in the Polish market. This is part of a commercial strategy of working across multiple levels of the value chain (manufacturer, formulator and distributor) for the supply of white label and own label branded products. This is the first step in taking OptiBiotix's own label GoFigure(R) products to international markets. This increases brand recognition and value in addition to creating a demand for SlimBiome(R), the functional ingredient within GoFigure(R) products. This means we are able to derive revenue from both the sale of our own brand GoFigure(R) products and SlimBiome(R)."

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For further information, please contact:

 
 OptiBiotix Health plc                                             www.optibiotix.com 
 Stephen O'Hara, Chief Executive                                 Contact via Walbrook 
                                                                                below 
 
 Cairn Financial Advisers LLP (NOMAD)                              Tel: 020 7213 0880 
 Liam Murray / Jo Turner 
 
   finnCap (Broker)                                                Tel: 020 7220 0500 
 Geoff Nash / Kate Bannatyne (Corporate Finance) 
 Camille Gochez (Corporate Broking) 
 
 Walbrook PR Ltd                      Tel: 020 7933 8780 or optibiotix@walbrookpr.com 
 Anna Dunphy                                                       Mob: 07876 741 001 
 
 

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

MSCUAANRKKAVUAR

(END) Dow Jones Newswires

May 22, 2019 02:00 ET (06:00 GMT)

1 Year Optibiotix Health Chart

1 Year Optibiotix Health Chart

1 Month Optibiotix Health Chart

1 Month Optibiotix Health Chart
Your Recent History
LSE
OPTI
Optibiotix..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20190619 00:38:43